Introduction
Psoriasis is a common, chronic, and recurrent skin disease with a characteristic clinical presentation consisting of inflammatory dermal-epidermal plaques. Disease severity and extension can be controlled by a range of well-established treatment modalities, including topical therapies, phototherapy, oral drugs, and biological agents. [1] [2] [3] [4] [5] In both American and European clinical guidelines, the two-compound agent containing calcipotriol (a vitamin D analog) and betamethasone dipropionate (a high potency corticosteroid) is the gold-standard first-line treatment for mild to moderate psoriasis. [1] [2] [3] [4] Phototherapy is often indicated in severe cases (≥10 points on the Psoriasis Area Severity Index [PASI] ) involving ≥10% of the body surface or in patients in whom topical treatments are ineffective. [1] [2] [3] [4] [5] Currently, narrow-band spectrum (311 nm) ultraviolet radiation (NB-UVB) is a first-line phototherapy technique, especially for plaque or guttate psoriasis, and this technique is also considered safe for breastfeeding women or children. 1, 5 Although both calcipotriol/ betamethasone and phototherapy are effective in treating psoriasis, to date no studies have directly compared these treatment options.
Given the lack of studies comparing phototherapy to topical treatments, the aim of this study was to compare the efficacy of Table 1 . All patients had a PASI of either 9 or 10.
All subjects provided written informed consent, and the study protocol was approved by the institutional review board at our university. Patients treated with calcipotriol/betamethasone were instructed to apply the ointment to all affected regions once daily for 8 weeks.
Treatment protocol
Exclusion criteria were as follows: age ≤18 years; hypersensitivity to light; body surface area (BSA) >30%; concomitant use of potentially phototoxic or photoallergic medicines; pregnancy; breastfeeding; skin neoplasm; or prior severe systemic disease. All patients who presented with scales before inclusion (3-5 days) used ointments or creams containing 5-10% urea or 5-10% salicylic acid. During treatment, the only additional therapies permitted were emollients.
The type of therapy undertaken was related to medical history (including all contraindication to phototherapy, especially taking phototoxic or photoallergic medicines) and social possibilities (NB-UVB was offered for patients who were able to travel to the clinic five times a week).
Clinical assessment
Disease severity in all patients was assessed on the PASI scale at baseline (pretreatment) and after the final treatment session. 
High-frequency ultrasound
In this study, we used a high-frequency ultrasound (HF-USG)
scanner at a frequency of 20 MHz, with a resolution of 60 lm 9 200 lm (axial 9 lateral) and approximately 15 mm penetration. A typical gain curve was 25-70 dB. The ultrasound velocity in the skin was set at 1.580 m/s. 8, 9 The main outcome parameter was subepidermal lower echogenic band (SLEB) thickness, which indicates the degree of skin inflammation. 8, 9 SLEB was evaluated in A-mode scanning by measuring the vertical distance between the lower edge of the entry echo and the posterior margin of the hypoechoic zone. 10, 11 All the scans were performed by the same trained observer (AP). HF-USG was administered to the same plaque assessed by TLS. All of the analyzed plaques/areas were scanned twice in the central region before and after phototherapy.
Statistical analysis
t Tests were used to compare means for the dependent and independent tests. The t test was used to evaluate the means of the dependent variables before and after treatment in each group. The t test was also used to perform between-group comparisons of the means of the independent trials. Pearson's correlation coefficient was used to measure correlations between variables. Statistical significance was set at P < 0.05. 
Results

Clinical assessments
There were no statistically significant differences in PASI scores between the groups (P = 0.2) at baseline. However, statistically significant differences between the groups were observed in pretreatment TLS (P = 0.008) as mean TLS values were higher in the ointment group (4.7 vs. 4.17) . No significant differences in PASI (P = 0.6) or TLS (P = 0.08) scores were observed between the groups after treatment finalization (Table 2 ).
Both treatments were equally effective in reducing PASI The clinical and ultrasonographic results are summarized in Table 2 .
HF-USG
Correlations Pre-and posttreatment SLEB thickness correlated positively with pre-and posttreatment PASI and TLS scores in both groups (Table 3) .
Conclusions
We conducted this real-life study to compare the relative effectiveness of calcipotriol/betamethasone versus phototherapy in a routine clinical practice in patients who presented PASI 9-10. It is well known that randomized controlled studies (RCTs) are recognized as a gold standard for evaluating treatment outcomes and guarantee highly selected patients and ideal conditions to be performed. 12 However, in a clinical practice, the practitioners should consider costs of therapy as well as their availability and many variables that can influence the outcomes. Also in everyday setting, there is no washout period for different topical agents, and patients are usually proposed to use new or Numerous studies have demonstrated the value of calcipotriol/betamethasone and NB-UVB in reducing the severity of psoriasis. [13] [14] [15] [16] [17] While calcipotriol/betamethasone is usually prescribed as a first-line treatment in mild to moderate psoriasis, NB-UVB is typically used in more severe cases or in patients who do not respond to topical therapies. [1] [2] [3] [4] [5] Although several studies have been performed to compare various phototherapy modalities, to date no direct comparisons of topical therapies and phototherapy have been carried out. [18] [19] [20] [21] [22] Moreover, only two studies have investigated NB-UVB used concurrently with topical therapies: one study evaluated NB-UVB combined with tazarotene, and another investigated NB-UVB with concurrent calcipotriol.
23,24
The present study demonstrates, for the first time, that UVB phototherapy and fixed combination calcipotriol/betamethasone are equally effective in the treatment of plaque psoriasis. In our sample of two similar subgroups of psoriatic patients (both with PASI scores of approximately 10 points), both treatment modalities yielded similar efficacy outcomes in terms of reduction of PASI (>80%) and TLS scores. However, although we found no statistically significant differences in final PASI scores, a greater proportion of patients treated with calcipotriol/betamethasone ointment reached PASI 75 (86% vs. 70%). PASI 90, which is becoming an increasingly used outcome measure, was achieved in approximately 17% of individuals in both groups.
Although some small but statistically significant differences were observed between the groups in baseline TLS scores (perhaps due to the simplicity of this scoring method), these differences were no longer present at the posttreatment analysis.
Interestingly, the calcipotriol/betamethasone group had better outcomes than reported in previous studies. 10, 11, [13] [14] [15] Specifically, the percentage reduction in PASI was higher in our study than in randomized control studies. [14] [15] [16] [17] By contrast, a smaller percentage of patients in our sample achieved plaque clearing or near clearing: 17% in our sample vs. up to 50% in other studies. 14, 15 The difference between randomized trials and our sample in terms of the percentage reduction in PASI (i.e., 73%
vs. 85%) may be due to the lack of a washout period for topical corticosteroids (as mentioned above, most of the patients were treated with potent topical steroids prior to inclusion), and to the duration of therapy (4 weeks in randomized trials vs. 8 weeks in our study).
14 Subjectivity of the PASI scale and the value of HF-USG as an objective measure Although we did not assess the inter-and intra-rater agreement on the PASI scale in the current study, many studies have reported high rates of disagreement; for this reason, PASI scores may not be fully reliable, especially when assessing patients with scores around 3. [24] [25] [26] In this sense, the PASI score seems to be a subjective measure, with substantial intraand inter-rater variability, particularly in evaluating erythema. 27, 28 The subjective nature of PASI scoring is an important drawback, and more objective, standardized methods are needed to more reliably determine psoriasis severity to select the most appropriate treatment. For this reason, we also used HF-USG, a noninvasive method, to quantify the disease process and to assess the effects of therapy. The value of ultrasonographic monitoring of psoriatic skin has been described previously in biological agents, oral drugs (e.g., cyclosporine), and topical medications (e.g., clobetasol propionate foam).
8,29-
33 HF-USG makes it relatively easy to distinguish between psoriatic and healthy skin because the affected skin is thicker and less echogenic, exhibiting a low echogenic band underneath the entrance echo (SLEB) and thick and irregular entry echo which is typical of inflammatory skin. 8, 9, 30 For this reason, we NB-UVB, narrowband ultraviolet; SLEB, subepidermal low echogenic band; PASI, Psoriasis Area and Severity Index; TLS; target lesion score.
used HF-USG to measure SLEB as an independent indicator of response. 9 The value of SLEB is that, as Gupta et al. observed, 8 the width reflects the thickness of the papillary dermis, which depends on the degree of vascularity, edema, and inflammation, and therefore indicates the clinical severity of the disease process. Prior to treatment initiation, we were able to detect SLEB in all of the psoriatic plaques, finding that this thickness decreased together with the reduction of PASI. Moreover, SLEB correlated positively with PASI and TLS. In only one case, we did not find a correlation between SLEB and TLS after NB-UVB, perhaps due to the simplicity of TLS. These findings, taken together, support the value of SLEB in evaluating the patient's overall condition and changes in the lesions. Moreover, SLEB can be objectively and quickly evaluated using specialized software, obviating the need to spend valuable time and effort on calculating scores. However, the main impediment to the routine use of HF-USG in clinical dermatology appears to be equipment cost.
Patients with PASI 9-10 are typically considered to be on the border as candidates for either topical or systemic therapy, especially if topical therapy fails. For this reason, the findings of the current study show that both calcipotriol/betamethasone and NB-UVB are equally effective in treating moderate psoriasis;
this is highly relevant because it provides clinicians with a wider range of treatment options in this patient profile, thus allowing for individualized therapy selection. For example, patients with poor compliance with topicals may benefit from NB-UVB, while cases in which NB-UVB is contraindicated (e.g., patients on photosensitizing drugs) can be treated with calcipotriol/betamethasone ointment.
The main finding of the current prospective study is that NB-UVB phototherapy and calcipotriol/betamethasone in ointment are equally effective in treating patients with plaque psoriasis in routine clinical practice. This finding is especially important in routine follow-up because physicians often need to propose alternative treatments in patients with recurrent disease. In addition, measurement of SLEB thickness with HF-USG may be a useful objective parameter to assess skin lesions.
